Daicel Corp 2019 AR2
The report outlines the Daicel Group's financial and non-financial performance for the fiscal year ended March 31, 2019, marking the company's 100th anniversary. Key highlights include the development of the Actranza lab, a needle-free drug delivery system utilizing pyrotechnic technologies, and the acquisition of genomics company Arbor Biosciences. The company also advanced its work-style reforms by reducing mandatory working hours and expanding telecommuting options. On the environmental front, Daicel reduced its domestic CO2 emissions by 2% year-on-year and achieved its landfill reduction targets ahead of schedule.
Company: Daicel Corp
Sector: Manufacturing
Country: Japan
Year: 2019
Type: AR2
Pages: 33
Back to company
Daicel Corp
Annual Report
The report outlines the Daicel Group's financial and non-financial performance for the fiscal year ended March 31, 2019, marking the company's 100th anniversary. Key highlights include the development of the Actranza lab, a needle-free drug delivery system utilizing pyrotechnic technologies, and the acquisition of genomics company Arbor Biosciences. The company also advanced its work-style reforms by reducing mandatory working hours and expanding telecommuting options. On the environmental front, Daicel reduced its domestic CO2 emissions by 2% year-on-year and achieved its landfill reduction targets ahead of schedule.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Apr 2018 - Mar 2019
Fiscal Year
2019
Published
Sep 1, 2019
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Women in Management
Employees